Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in CRSP.
← Back to Free Index

CRSP

Analysis as of: 2026-05-07
CRISPR Therapeutics AG
CRISPR Therapeutics develops gene-edited medicines, led by CASGEVY with Vertex and a wholly owned pipeline in cardiovascular, autoimmune, oncology, regenerative and rare disease programs.
biotech healthcare
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Approved proof, but rerating needs a second franchise
The upside case is a transition from first-product credibility to a second, self-directed franchise. Recent updates keep that path alive, but they also confirm that clinical proof and treatment throughput remain the gating variables.

Analysis

Thesis
The five-year upside is not CASGEVY alone; it is the move from first approved CRISPR proof into a second, internally controlled franchise, with platform reuse, manufacturing know-how and smarter deal structure turning scientific credibility into direct revenue capture.
Last Economy Alignment
AI should improve target selection, program design and portfolio speed, while value capture stays anchored in regulated medicines, clinical data, IP and manufacturing rather than commoditized software. The main limits are still biology, regulation and treatment-center throughput.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.9x (from 5 most recent analyses)
Reasoning
The rerating case does not require every program to work. It requires CASGEVY to become a credible profit stream, one wholly owned in vivo or cell-therapy asset to cross into clear commercial relevance, and the platform to earn better partnership economics without heavy dilution. That can move the company from cash-backed optionality to a de-risked multi-asset editing business, but the need for second-franchise proof keeps upside below the most explosive biotech outcomes.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is proof conversion, not survival. CRISPR has enough resources to stay in the game, but the stock still needs one wholly owned program to move from promising biology into durable efficacy, manageable safety and scalable economics. If CASGEVY stays partner-throttled and the owned pipeline remains early, investors may keep valuing the company as cash plus optionality rather than a durable franchise.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.44
They own valuable gene-editing know-how, clinical packages and some manufacturing, so AI can help them design faster without making the medicine easy to copy. But the real bottlenecks are still proof in patients, regulators and getting complex therapies through treatment centers.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$64.82
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case